Current Perspective On the Use of Calcium Channel Blockers to Treat Hypertensive Patients: the Role of Lercanidipine

References

• Williams B , ManciaG, SpieringWet al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology, ESH/ESC Task Force for the Management of Arterial Hypertension. J. Hypertens., 36(12), 2284–2309 (2018).
   PubMed Web of Science ®Google Scholar
• Thomopoulos C , ParatiG, ZanchettiA. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs – overview and meta-analyses. J. Hypertens., 33, 195–211 (2015).
   PubMed Web of Science ®Google Scholar
• Thomopoulos C , ParatiG, ZanchettiA. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses. J. Hypertens., 33(7), 1321–1341 (2015).
   PubMed Web of Science ®Google Scholar
• Morgan TO , AndersonAI, MacInnisRJ. ACE inhibitors, β-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am. J. Hypertens., 14(3), 241–247 (2001).
   PubMed Web of Science ®Google Scholar
• Wong ND , LopezVA, L’ItalienG, ChenR, KlineSE, FranklinSS. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch. Intern. Med., 167(22), 2431–2436 (2007).
   PubMedGoogle Scholar
• Barrios V , EscobarC, CalderónAet al. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J. Hum. Hypertens., 21(6), 479–485 (2007).
   PubMed Web of Science ®Google Scholar
• Messerli FH , KetelhutR. Left ventricular hypertrophy, an independent risk factor. J. Cardiovasc. Pharmacol., 17, S59–S66; discussionS66–S67 (1991).
   Web of Science ®Google Scholar
• Klingbeil AU , SchneiderM, MartusP, MesserliFH, SchmiederRE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med., 115(1), 41–46 (2003).
   PubMed Web of Science ®Google Scholar
• Klag MJ , WheltonPK, RandallBLet al. Blood pressure and end-stage renal disease in men. N. Engl. J. Med., 334(1), 13–18 (2006).
   Google Scholar
• Blood Pressure Lowering Treatment Trialists’ Collaboration , NinomiyaT, PerkovicVet al.Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease, meta-analysis of randomised controlled trials. Brit. Med. J., 347, f5680 (2013).
   PubMed Web of Science ®Google Scholar
• Sabbatini M , LeonardiA, TestaR, VitaioliL, AmentaF. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension., 35(3), 775–779 (2000).
   PubMed Web of Science ®Google Scholar
• Agabiti-Rosei E , HeagertyAM, RizzoniD. Effects of antihypertensive treatment on small artery remodelling. J. Hypertens., 27(6), 1107–1114 (2007).
   Web of Science ®Google Scholar
• Thomopoulos C , ParatiG, ZanchettiA. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs, meta-analyses of randomized trials. J. Hypertens., 34(10), 1921–1932 (2016).
   PubMed Web of Science ®Google Scholar
• Borghi C . Lercanidipine in hypertension. Vasc. Health Risk Manag., 1(3), 173–182 (2005).
   PubMedGoogle Scholar
• Cicero AF , GerocarniB, RosticciM, BorghiC. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin. Exp. Hypertens., 34(2), 113–117 (2012).
   PubMed Web of Science ®Google Scholar
• Barrios V , NavarroA, EsterasAet al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press., 11(2), 95–100 (2002).
   PubMed Web of Science ®Google Scholar
• Grassi G , RoblesNR, SeravalleG, FiciF. Lercanidipine in the management of hypertension, an update. J. Pharmacol. Pharmacother., 8(4), 155–165 (2017).
   PubMedGoogle Scholar
• Leonetti G , MagnaniB, PessinaACet al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am. J. Hypertens., 15(11), 932–940 (2002).
   PubMed Web of Science ®Google Scholar
• Mancia G , ParodiA, MerlinoL, CorraoG. Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. J. Hypertens., 29(5), 1012–1018 (2011).
   PubMed Web of Science ®Google Scholar
• Ambrosioni E , LeonettiG, PessinaAC, RappelliA, TrimarcoB, ZanchettiA. Patterns of hypertension management in Italy, results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J. Hypertens., 18(11), 1691–1699 (2000).
   PubMed Web of Science ®Google Scholar
• Mancia G , OmboniS, ChazovaIet al. Effects of the lercanidipine-enalapril combination vs the corresponding monotherapies on home blood pressure in hypertension, evidence from a large database. J. Hypertens., 34(1), 139–148 (2016).
   PubMed Web of Science ®Google Scholar
• Rizzoni D . Dose–response effect of the lercanidipine/enalapril combination, a pooled analysis. Curr. Med. Res. Opin., 32(Suppl. 2), 17–23 (2016).
   PubMedGoogle Scholar
• De Ciuceis C , SalvettiM, RossiniCet al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J. Hypertens., 32(3), 565–574 (2014).
   PubMed Web of Science ®Google Scholar
• Bakris GL , SarafidisPA, WeirMRet al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH), a prespecified secondary analysis of a randomised controlled trial. Lancet, 375(9721), 1173–1181 (2010).
   PubMed Web of Science ®Google Scholar
• Dalla Vestra M , PozzaG, MoscaAet al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria, DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr. Metab., 17(5), 259–266 (2004).
   PubMedGoogle Scholar
• Robles NR , OconJ, GomezCFet al. Lercanidipine in patients with chronic renal failure, the ZAFRA study. Ren. Fail., 27(1), 73–80 (2005).
   PubMed Web of Science ®Google Scholar
• Robles NR , RomeroB, de VinuesaEG, Sánchez-CasadoE, CuberoJJ. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren. Fail., 32(2), 192–197 (2010).
   PubMed Web of Science ®Google Scholar
• Robles NR , CalvoC, SobrinoJet al. Lercanidipine valuable effect on urine protein losses, the RED LEVEL study. Curr. Med. Res. Opin., 32(Suppl. 2), 29–34 (2016).
   PubMedGoogle Scholar
• Hayashi K , WakinoS, SuganoN, OzawaY, HommaK, SarutaT. Ca2+ channel subtypes and pharmacology in the kidney. Circ. Res., 100(3), 342–353 (2007).
   PubMed Web of Science ®Google Scholar
• Cerbai E , MugelliA. Lercanidipine and T-type calcium current. Eur. Rev. Med. Pharmacol. Sci., 22(12), 4025–4031 (2018).
   PubMed Web of Science ®Google Scholar
• Zamponi GW , StriessnigJ, KoschakA, DolphinAC. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol. Rev., 67(4), 821–870 (2015).
   PubMed Web of Science ®Google Scholar